cipate in any potential future 
capital increase. As at December 31, 2023, the Group recognises 
a tax expense for an amount of EUR 8.8 million 
representing -2792.1% of the result before tax. In the Proton Therapy and Other Accelerators 
segment, the tax charge results from the 
progress on installation projects and the 
recognition of the related revenue and margin in 
some countries with a relatively high tax rate as 
well as a partial reversal of the deferred tax 
assets in Belgium for EUR 1.7 million. === Page 132 ===
IBA Annual Report 2023 
129. 4.2.